Emily J Gallagher, MD Email Emily Gallagher
- ASSISTANT PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
- Endocrine, Diabetes and Bone Diseases
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Emily J. Gallagher earned her MB BCh BAO (MD equivalent) with honors from University College Dublin, Ireland and her PhD in Physiology from the Royal College of Surgeons of Ireland. She is a member of the Royal College of Physicians of Ireland (MRCPI), is Board Certified in Internal Medicine and Endocrinology. Dr. Gallagher trained in Internal Medicine and Endocrinology at the Mater Miseriordiae University Hospital, Dublin, and completed her postgraduate training in Internal Medicine and Endocrinology at Mount Sinai. She was Chief Fellow in Endocrinology, and was subsequently appointed Assistant Professor of Medicine Endocrinology, Diabetes and Bone Diseases. As a fellow she was awarded the Endocrine Fellows Foundation, Fellows Development Research Grant in 2010. In 2014, she received a K08 Clinician-Scientist Career Development Award from the NIH / NCI to study the role of hyperlipidemia in breast cancer progression. In 2016 she received a Tisch Cancer Institute at Mount Sinai Junior Scientist Research Award to study the role of lipid metabolites in cancer. In 2017 she received a Mount Sinai Department of Medicine Junior Faculty Translational Collaborative Research Pilot Award to study the mechanisms underlying the development of endocrine immune related adverse events in oncology patients treated with immune checkpoint inhibitors. She received the Harold and Golden Lamport Research Award in 2017.
Please visit the Gallagher Laboratory.
Dr. Gallagher specializes in Onco-Endocrinology: the treatment of endocrine complications of oncology treatments.
These complications of oncology treatments include: type 1 and type 2 diabetes, thyroid dysfunction, pituitary dysfunction, adrenal insufficiency, dyslipidemia, amenorrhea, disorders of calcium and bone.
American Board of Internal Medicine
- Oncological Endocrine Issues
- Type 1 Diabetes
- Type 2 Diabetes
MD, University College Dublin
Fellowship, Mater Misericordiae University Hospital
MD, University College Dublin
MRCPI, Royal College of Physicians
PhD, Royal College of Surgeons
Residency, Mater Misericordiae University Hospital
Residency, Internal Medicine
Mount Sinai Hospital
Mount Sinai Hospital
A complete list of Dr. Gallagher's Publications can be found at:
Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, LeRoith D. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013 Feb; 32(8).
Ferguson R, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, Leroith D. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2/Neu-mediated breast cancer. Endocrine-related cancer 2013 Apr;.
Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 2012 Jul; 31(27).
Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. The Medical clinics of North America 2011 Sep; 95(5).
Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology 2011 Jul; 152(7).
Gallagher EJ, LeRoith D. Is growth hormone resistance/IGF-1 reduction good for you?. Cell metabolism 2011 Apr; 13(4).
Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends in endocrinology and metabolism: TEM 2010 Oct; 21(10).
Lann D, Gallagher E, Leroith D. Insulin resistance and the metabolic syndrome. Minerva medica 2008 Jun; 99(3).
Via MA, Gallagher EJ, Mechanick JI. Bone physiology and therapeutics in chronic critical illness. Annals of the New York Academy of Sciences 2010 Nov; 1211.
Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. The Mount Sinai journal of medicine, New York; 77(5).
Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Current diabetes reports 2010 Apr; 10(2).
Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. Journal of diabetes 2009 Mar; 1(1).
LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2008 Sep; 116 Suppl 1.
Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinology and metabolism clinics of North America 2008 Sep; 37(3).
Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists; 16(5).
Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 2011 Dec; 1243.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Gallagher did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.